Document Detail


Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.
MedLine Citation:
PMID:  16319987     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have examined the role of cyclin D1 and cyclin-dependent kinase-4 (CDK4) in the cell cycle progression and proliferation of MCF-7 breast cancer cells. Forced expression of cyclin D1 using a tetracycline-regulated expression system, and suppression of endogenous cyclin D1 and CDK4 using small interfering RNA (siRNA) were used to validate this protein complex as a drug target in cancer drug discovery. Overexpression of cyclin D1 increased both phosphorylation of the retinoblastoma gene product (RB) and passage through the G1-S phase transition, resulting in increased proliferation of cells. When cyclin D1 expression was shut off, growth rates fell below those seen in control cell lines transfected with the vector, indicating an increased dependence on this protein for proliferation. Inhibition of endogenous cyclin D1 or CDK4 expression by RNA interference resulted in hypophosphorylation of RB and accumulation of cells in G1. These results support the prevailing view that pharmacological inhibition of cyclin D1/CDK4 complexes is a useful strategy to inhibit the growth of tumors. Furthermore, since MCF-7 cells appear to be dependent on this pathway for their continued proliferation, it is a suitable cell line to test novel cyclin D1/CDK4 inhibitors.
Authors:
Mary Grillo; Matthew J Bott; Neha Khandke; John P McGinnis; Miriam Miranda; Muthupalaniappan Meyyappan; Edward C Rosfjord; Sridhar K Rabindran
Related Documents :
10465067 - The cdk9-associated cyclins t1 and t2 exert opposite effects on hiv-1 tat activity.
8187637 - A drosophila g1-specific cyclin e homolog exhibits different modes of expression during...
12875657 - Expression of cyclins a, e and topoisomerase ii alpha correlates with centrosome amplif...
15175247 - Hua enhancer3 reveals a role for a cyclin-dependent protein kinase in the specification...
17363137 - Use of hecate-chorionic gonadotropin beta conjugate in therapy of lutenizing hormone re...
22352427 - The expression of podoplanin and classic cadherins in the mouse brain.
Publication Detail:
Type:  Journal Article     Date:  2005-12-01
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  95     ISSN:  0167-6806     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-03-27     Completed Date:  2006-10-24     Revised Date:  2012-06-25    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  185-94     Citation Subset:  IM    
Affiliation:
Oncology Research, Wyeth Research, Pearl River, NY 10965, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breast Neoplasms / genetics,  metabolism*
Cell Proliferation
Cyclin D1 / antagonists & inhibitors,  genetics,  metabolism*
Cyclin-Dependent Kinase 4 / antagonists & inhibitors,  genetics,  metabolism*
Female
G1 Phase
Gene Silencing
Humans
Immunoprecipitation
Phosphorylation
RNA, Small Interfering / pharmacology*
Retinoblastoma Protein / metabolism
Tetracycline / pharmacology
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/RNA, Small Interfering; 0/Retinoblastoma Protein; 136601-57-5/Cyclin D1; 60-54-8/Tetracycline; EC 2.7.11.22/CDK4 protein, human; EC 2.7.11.22/Cyclin-Dependent Kinase 4

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  From genetic abnormality to metastases: murine models of breast cancer and their use in the developm...
Next Document:  Pre-diagnosis physical activity and mammographic density in breast cancer survivors.